Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 20
- Registration Number
- NCT03993964
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1192
- Registration Number
- NCT03980054
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Not Applicable
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03947242
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03933982
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT03923166
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT03923179
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
Phase 2
- Conditions
- Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerBreast DiseasesHormone Receptor Positive Tumor
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03910712
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Phase 2
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT03876587
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03843749
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
FUSCC Refractory TNBC Umbrella (FUTURE)
Phase 1
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)Drug: PARP inhibitor included therapyDrug: BLIS with anti-VEGFR included therapy
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT03805399
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath